BB-1712 / BlissBio - LARVOL DELTA

Preclinical studies of BB-1712: A B7H3-targeting eribulin-containing ADC with the potential to overcome resistance to DNA topoisomerase I inhibitor-containing ADCs (AACR 2025) - "In this study, we introduce BB-1712, a novel B7-H3-targeting ADC that incorporates eribulin as its cytotoxic payload, with the potential to treat patients not sensitive to ADCs containing DNA topoisomerase I inhibitors as payload toxin such as DS-7300a. Pharmacokinetic and toxicology assessments in non-human primates revealed a favorable safety profile for BB-1712 at clinically relevant dosages and administration schedules.In summary, our findings suggest that BB-1712 has promising preclinical efficacy and safety profiles as well as the potential to circumvent resistance mechanisms associated with current therapies. These results support the advancement of BB-1712 into clinical trials for patients with B7-H3-expressing solid tumors."

Preclinical • Breast Cancer • Gastric Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Small Cell Lung Cancer • Solid Tumor • CD276

The IND application of Bioscan's innovative ADC drug BB-1712 was approved by the China National Medical Products Administration [Google translation] (pharnexcloud.com) - "On November 14, 2024, China time, BlissBio's innovative tumor-targeted antibody-drug conjugate (ADC) BB-1712 Phase I clinical trial application (IND) was approved by the China National Medical Products Administration (NMPA) (acceptance number: CXSL2400589). BB-1712 is an innovative ADC targeting B7-H3 and using eribulin as a toxin, and is intended to be developed for the treatment of a variety of solid tumors."

New P1 trial • Oncology • Solid Tumor

The IND application of Bioscan’s innovative ADC drug BB-1712 was approved by the US FDA [Google translation] (vbdata.cn) - "Bioscan's innovative ADC drug BB-1712 has been approved by the U.S. FDA for its Phase I clinical trial application. It is intended to be used to treat a variety of solid tumors. The company looks forward to its subsequent clinical research performance."

IND • Oncology • Solid Tumor